Abstract:Objective To assess the therapeutic effects of flupentixol and melitracen tablets combined with Saccharomyces boulardii on patients with diarrhea-predominant irritable bowel syndrome (IBS) accompanied with anxiety and depression.Methods This multi-center,randomized,prospective study enrolled 84 patients with diarrhea-predominant IBS who were divided into combined treatment group (42 patients) and control group (42 patients).Saccharomyces boulardii was administrated in both of the groups,and flupentixol and melitracen was added in combined treatment group.The treatment course was four weeks.The gastrointestinal symptoms and mood disorders were evaluated before treatment,one week and four weeks after treatment.Adverse reactions were also observed.Chi-square test was performed for statistical analysis.Results At the end of one week after treatment,the efficacy rates of gastrointestinal symptoms improvement of combined treatment group and control group were 31.0％ (13/42) and 23.8％ (10/42),and there was no statistically significant difference (P＞0.05).At the end of four weeks after treatment,the efficacy rate of gastrointestinal symptoms improvement of combined treatment group was 92.5％ (37/40),which was higher than that of control group (73.2％,30/41),and the difference was statistically significant (x2 =5.291,P =0.037).At the end of one week after treatment,the efficacy rates of Hamilton Depression Scale score improvement of combined treatment group and control group were 31.6％ (12/38) and 12.1％ (4/33),and there was no statistically significant difference (P＞0.05).At the end of four weeks after treatment,the efficacy rates of Hamilton Depression Scale score improvement of combined treatment group was 63.9％ (23/36),which was higher than that of control group (34.4％,11/42),and the difference was statistically significant (x2 =6.433,P=0.043).At the end of one week and four weeks after treatment,the efficacy rates of Hamilton Depression Scale score improvement of combined treatment group were 35.7％ (15/42) and 80.0％ (32/40),which were higher than those of control group (15.4％,6/39 and 34.2％,13/38),and the differences were statistically significant (x2 =9.759,P=0.007; x2 =17.105,P＜0.01).One week after treatment,the adverse events rates of combined treatment group and control group were 4.8％ (2/42) and 4.8％ (2/42) ; four weeks after treatment,the adverse events rates of combined treatment group and control group were 2.5％ (1/40) and 2.4％ (1/41).There was no statistically significant difference in adverse events rates between two groups (both P＞0.05).Conclusions Flupentixol and melitracen combined with Saccharomyces boulardii treatment could not only improve the anxiety and depression symptoms of patients with diarrhea-predominant IBS,but also effectively improve gastrointestinal symptoms.The efficacy of combined treatment is better than monotherapy Saccharomyces boulardii alone treatment.

A clinical trial of fFluoxetine and Paroxetine for the treatment of the irritable bowel syndrome

A Clinical Trial of Alprazolam and Fluoxetine for the Treatment of Severe Refractory Irritable Bowel Syndrome

Treatment of Irritable Bowel Syndrome with Drotaverine Hydrochloride: A Multicentre Clinical Trial

Efficacy of fluoxetine combined with psychological intervention for treatment of depressive patients with insomnia

A clinical trial of alprazolam and fluoxetine for the treatment of the intractable functional gastrointestinal disorders

A Meta-analysis of Efficacy and Adverse Reactions of Paroxetine and Fluoxetine in Patients with Depression

The curative effect of paroxetine in treatment of anxiety and depression disorder in Sj gren's syndrome patients

Doxepin(71 Patients) Vs Pancreatin (32 Patients) in Treatment of Irritable Bowel Syndrome

Comparative study on paroxetine combined with folic acid and paroxetine in the treatment of primary premature ejaculation and plasma 5-HT level

Evaluation of therapeutic effects of flupentixol and melitracen combined with Saccharomyces boulardii on patients with diarrhea-predominant irritable bowel syndrome accompanied with anxiety and depression

EFFECT OF PAROXETINE COMBINED WITH QUETIAPINE IN THE TREATMENT OF DEPRESSION WITH PHYSICAL SYMPTOMS

A Control Study of Paroxetine Combined with Aripiprazoie in the Treatment of Depression.

A controlled study in the treatment of depression with escitalopram and paroxetine

A Probiotic Treatment Containing Lactobacillus, Bifidobacterium and Enterococcus Improves IBS Symptoms in an Open Label Trial

Efficacy and safety of enteric-coted sustained release tablets in the treatment of major depression

Duloxetine Enteric-coated Tablets Versus Paroxetine in the Treatment of Major Depressive Disorder: A Double-blind, Double-dummy, Randomized Controlled Clinical Trial

Unveiling the efficacy of paroxetine and gabapentin in ulcerative colitis patients in remission with co-existing IBS-like symptoms: a single-blinded randomized clinical trial

A Comparison Study of Citalopram Versus Paroxetine in Treatment of Generalized Anxiety Disorder

Short-Term Effects of Flupentixol-Melitracen on Regional Brain Function in Patients with Irritable Bowel Syndrome: an Fmri Study

Systematic Review of Paroxetine in the Treatment of Somatization Disorder

Comparative Efficacies of Fluoxetine and Paroxetine in Major Depression Across Varying Acute-Phase Treatment Periods: a Meta-Analysis.